#Warsaw #Poland #Aurora Cannabis #medical cannabis #Black Jelly

Aurora Cannabis Expands Its Product Range with Black Jelly in Poland

Aurora Cannabis Inc., a leading Canadian corporation in the medical cannabis sector, has recently announced the introduction of a new proprietary cultivar, Black Jelly, to the Polish market. This strategic move is part of Aurora's continuous effort to enhance its portfolio of high-potency medical cannabis products in one of the fastest-growing markets in Europe.

Aurora is recognized for its advanced cultivation techniques and quality standards, operating within facilities that are certified under GACP (Good Agricultural and Collection Practices) and EU-GMP (European Union Good Manufacturing Practice). The launch of Black Jelly signifies Aurora’s commitment to providing superior medical cannabis options to health care providers and their patients in Poland.

According to Andreas Dotterweich, Senior Vice President of Aurora Europe, this new cultivar reflects the company’s dedication to meeting the demands of prescribers. He stated, "We deeply understand that prescribers want reliable, high-potency medical cannabis options for their patients, and we're proud to offer superior products that consistently meet prescriber and patient needs."

The New Black Jelly Cultivar

Black Jelly is characterized by a notable cannabinoid profile, featuring THC levels at 27% and negligible CBD content (<1%). This high-THC sativa strain derives from Alien Cake 3030 crossed with T037 and is celebrated for its dense, large buds that showcase vibrant green and orange hues. The cultivar is particularly appealing thanks to its unique terpene profile, which bears the sweet aromatic notes of black liquorice complemented by fruity undertones.

The cultivation of Black Jelly utilizes premium hang-drying and curing techniques, which are crucial in preserving the desirable attributes of the flower. As one of the main offerings under the Cannabis flos Aurora brand, Black Jelly joins other popular strains such as Farm Gas and Sourdough, reinforcing Aurora's standing as a trusted source for medical cannabis.

Aurora's Ongoing Commitment to Patient Access

With more than a decade of experience in the international medical cannabis arena, Aurora continues to establish its leadership by combining scientific expertise with regulatory knowledge. This dual focus enables the company to support patient access and foster market expansion across Europe effectively. Aurora’s robust portfolio not only caters to medical needs but also crosses into adult-use markets, expanding its influence and accessibility.

The introduction of Black Jelly is part of a broader initiative by Aurora to respond to the growing demand for high-quality medical cannabis in Poland. As patient awareness and prescription practices evolve, Aurora aims to be at the forefront, ensuring that both healthcare providers and patients have access to innovative and effective medical cannabis solutions.

In conclusion, the launch of Black Jelly not only enhances Aurora’s product offerings but also signifies an important step in promoting patient welfare in the rapidly evolving landscape of medical cannabis. The company remains committed to opening new markets while adhering to high standards of quality and safety in its cannabis products. As Aurora moves forward, its innovative approach serves as a model for others in the industry, highlighting the importance of understanding and meeting patient needs in a dynamic regulatory environment.